NABUMETONE TABLET

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

NABUMETONE

Dostupno od:

SANIS HEALTH INC

ATC koda:

M01AX01

INN (International ime):

NABUMETONE

Doziranje:

500MG

Farmaceutski oblik:

TABLET

Sastav:

NABUMETONE 500MG

Administracija rute:

ORAL

Jedinice u paketu:

100

Tip recepta:

Prescription

Područje terapije:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Proizvod sažetak:

Active ingredient group (AIG) number: 0122821001; AHFS:

Status autorizacije:

CANCELLED POST MARKET

Datum autorizacije:

2017-02-08

Svojstava lijeka

_ _
_Product Monograph –Nabumetone _
_Page 1 _
PRODUCT MONOGRAPH
PR
NABUMETONE
(NABUMETONE TABLETS, BP)
500 MG
NONSTEROIDAL ANTI-INFLAMMATORY AGENT
Sanis Health Inc.
Date of Revision: June 6, 2013
333 Champlain Street, Suite 102
Dieppe, New Brunswick
E1A 1P2
Control No.:
164965
_ _
_Product Monograph –Nabumetone _
_Page 2_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
9
DRUG INTERACTIONS
.................................................................................................
13
DOSAGE AND ADMINISTRATION
.............................................................................
14
OVERDOSAGE
...............................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 14
STORAGE AND STABILITY
.........................................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 17
PART II: SCIENTIFIC INFORMATION
...............................................................................
18
PHARMACEUTICAL INFORMATION
.........................................................................
18
CLINICAL TRIALS
.........................................................................................................
19
DETAILED PHARMACOLOGY
..........................